My guest this week is James Lanthier, CEO of Mindset Pharma of Toronto, Canada, a company that is seeking to develop novel psychedelic analogues to existing psychedelics such as psilocybin, DMT, and 5-MeO-DMT for more targeted delivery, efficacy, and therapeutic potential for use in the developing psychedelic healthcare field. You can find them online at www.mindsetpharma.com
My guest this week is James Lanthier, CEO of Mindset Pharma of Toronto, Canada, a company that is seeking to develop novel psychedelic analogues to existing psychedelics such as psilocybin, DMT, and 5-MeO-DMT for more targeted delivery, efficacy, and therapeutic potential for use in the developing psychedelic healthcare field. You can find them online at www.mindsetpharma.com
